Core Insights - The recent quarterly reports from public funds indicate a significant increase in equity positions, reflecting fund managers' positive outlook on market opportunities [1][6][7] Group 1: Fund Performance - The "champion fund" Yongying Technology Smart Mixed Fund reported a total scale of 11.52 billion yuan, a remarkable increase of 888.09% from the previous quarter [4] - The fund's equity investment ratio rose to 91.59%, up from 86.38% in the previous quarter, indicating a strong bullish sentiment [4] - The top three holdings of the fund include Xinyi Technology, Zhongji Xuchuang, and Tianfu Communication, with respective market values of 1.125 billion yuan, 1.092 billion yuan, and 1.034 billion yuan [4] Group 2: Sector Focus - The Yongying Technology Smart Mixed Fund's manager highlighted the ongoing potential in the global cloud computing industry and the increasing value of AI models [5] - The Longcheng Pharmaceutical Industry Selected Mixed Fund also increased its equity investment ratio to 82.18%, focusing on innovative pharmaceutical stocks in the Hong Kong market [6] - The top three holdings of the Longcheng fund include Innovent Biologics, 3SBio, and Hotgen Biotech, with significant year-to-date gains [6] Group 3: Market Outlook - The technology sector, particularly cloud computing and artificial intelligence, is expected to benefit from accelerated digital transformation and strong market demand [7] - The innovative pharmaceutical sector in Hong Kong is poised for growth due to rising global healthcare demands and advancements in China's biopharmaceutical capabilities [7] - Both sectors are viewed as having broad investment windows, with potential for sustained value creation as technology progresses and consumer upgrades occur [7]

Core Insights - The Hong Kong stock market experienced a pullback on October 22, with the Hong Kong Stock Connect Innovative Drug ETF (520880) declining by 2.74% despite a significant $11.4 billion business development deal involving Innovent Biologics [1][3] - The trading volume for the ETF reached 374 million HKD, a 30% increase from the previous period, indicating strong buying interest [1] - Innovent Biologics announced a strategic partnership with Takeda Pharmaceutical worth $11.4 billion, marking a record for business development transactions in China's innovative drug sector [3] Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high but closed lower, losing its 5-day moving average [1] - Major stocks within the ETF saw mixed performance, with Innovent Biologics down 1.96% despite high trading volume of 6.288 billion HKD, while other significant stocks like CSPC Pharmaceutical and BeiGene fell over 2% [1][3] Investment Trends - The ETF is designed to track the Hang Seng Hong Kong Stock Connect Innovative Drug Selective Index, which focuses exclusively on innovative drug development companies, with over 70% of its holdings in large-cap leaders [3][4] - The index has shown strong performance, with a year-to-date increase of 108.14%, outperforming other innovative drug indices [4][5] - Analysts suggest that the recent surge in business development transactions may alleviate market concerns and highlight the long-term growth potential of China's innovative drug sector [3]

Market Overview - The market experienced a day of low trading volume with all three major indices retreating, while the Shanghai Composite Index slightly fell by 0.07% but managed to hold above the 3900-point mark [1] - A-shares saw a trading volume of less than 1.7 trillion yuan, marking the lowest level since August 6 [1] - The banking sector showed resilience, with Agricultural Bank of China rising by 2.66%, achieving a 14-day consecutive increase and setting a new historical high [1][3] Banking Sector - The double-hundred billion bank ETF (512800) recorded a strong performance with a 10-day consecutive rise, closing up 0.85% with a trading volume of 1.189 billion yuan [5][7] - A total of 42 bank stocks in A-shares saw 39 gainers and 3 losers, indicating strong sector performance [3] - The banking sector's price-to-book ratio (PB) is at 0.71, which is in the lower range of the past decade, and the dividend yield stands at 4.04%, enhancing its attractiveness amid rising market uncertainties [6][7] AI Sector - The AI sector showed signs of activity with the "AI twins" - the ChiNext AI ETF (159363) and the Sci-Tech Innovation AI ETF (589520) both experiencing intraday gains exceeding 1% [1] - The total market capitalization of Cambricon Technologies has returned to 600 billion yuan, with its stock rising over 4% [9] - The Sci-Tech Innovation AI ETF (589520) saw a maximum intraday increase of 1.33%, reflecting strong interest in the domestic AI industry chain [11] Innovative Drug Sector - A significant milestone was reached with Innovent Biologics securing a record-breaking 11.4 billion USD business development deal, marking a new high for Chinese innovative drug BD transactions [3][19] - Despite the overall market retreat, the Hong Kong Stock Connect innovative drug ETF (520880) experienced strong buying interest, with a trading volume of 374 million yuan, indicating a potential "bottom-fishing" sentiment [17][19] - The innovative drug sector is expected to remain active, especially in the fourth quarter, which historically sees concentrated BD transactions [19]

Core Viewpoint - The Hong Kong stock market experienced a pullback despite a significant $11.4 billion strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, marking a record for Chinese innovative drug business development (BD) transactions [3]. Group 1: Market Performance - The Hong Kong Innovation Drug ETF (520880) opened high but closed down 2.74%, losing its 5-day moving average, despite a trading volume of 374 million HKD, which increased by 30% compared to the previous period [1]. - The ETF has seen high capital inflow recently, with 7 out of the last 10 trading days attracting a total of 176 million HKD [1]. - Major stocks within the ETF, such as Innovent Biologics, saw a trading volume of 6.288 billion HKD, marking a historical high, but closed down 1.96% with a volatility exceeding 13% [1]. Group 2: Strategic Collaborations - Innovent Biologics announced a groundbreaking $11.4 billion global strategic partnership with Takeda Pharmaceutical to accelerate the development of next-generation IO and ADC therapies, setting a new record for BD transactions in China's innovative drug sector [3]. - Analysts noted that despite the market's downturn, the high premium on the ETF indicates that "bottom-fishing" capital is already in action, highlighting the current value in innovative drug investments [3]. Group 3: ETF Composition and Performance - The Hong Kong Innovation Drug ETF (520880) passively tracks the Hang Seng Hong Kong Innovation Drug Select Index, which exclusively invests in innovative drug development companies, with over 70% of its holdings in large-cap innovative drug leaders [4]. - The top ten constituent stocks account for 71.63% of the ETF's weight, showcasing a significant concentration in leading companies [5]. - As of the end of September, the Hang Seng Hong Kong Innovation Drug Select Index has risen 108.14% year-to-date, outperforming other innovative drug indices [6].

Group 1: Fund Performance and Holdings - The performance of the "Champion Fund" Yongying Technology Smart Selection has seen a remarkable increase, with a year-to-date return of nearly 195% and a net asset value growth of 234% since its inception [2][3][9] - The fund's scale surged nearly tenfold in the third quarter, growing from 1.166 billion to 11.521 billion yuan, with the number of shares increasing from 700 million to 3.466 billion [5][9] - The fund maintains a high stock position, with over 91% in equities, focusing heavily on the cloud computing sector [2][3] Group 2: Key Holdings in Cloud Computing - The top three holdings of Yongying Technology Smart Selection include Xinyi Technology, Zhongji Xuchuang, and Tianfu Communication, each with a market value exceeding 1 billion yuan [3][2] - Significant increases in holdings were observed for Huadian Co., Taicheng Light, and Tianfu Communication, with growth rates of 502.17%, 642.80%, and 347.47% respectively [3][2] Group 3: Longcheng Pharmaceutical Industry Selection - Longcheng Pharmaceutical Industry Selection has also performed well, achieving a return of 102.02% in the first three quarters, qualifying it as a "doubling fund" [7][9] - The fund's scale increased from 1.132 billion to 1.790 billion yuan in the third quarter, marking a growth of nearly 60% [9] - The fund's top three holdings include Innovent Biologics, 3SBio, and Hotgen Biotech, with each holding a market value exceeding 100 million yuan [8][7] Group 4: Investment Focus and Strategy - The investment strategy of Yongying Technology Smart Selection emphasizes the cloud computing industry, with a focus on optical communication and PCB sectors, anticipating significant technological advancements by 2027 [6][2] - Longcheng Pharmaceutical Industry Selection is shifting its focus towards clinical data, overseas licensing, and domestic sales, indicating a strategic pivot towards non-oncology sectors [9][7]

Market Overview - The market opened lower and experienced low-volume fluctuations, with Hong Kong pharmaceutical stocks declining due to market sentiment despite positive news regarding overseas expansion [1] - The Hong Kong Stock Connect Innovation Drug ETF (159570) fell over 2%, with a trading volume exceeding 1.6 billion yuan during the session [1] - As of October 21, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) exceeded 20.9 billion yuan, maintaining a leading position in scale and liquidity among peers [1] Strategic Collaborations - Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical to accelerate the development of its next-generation IO and ADC therapies, including two late-stage candidates and one early-stage project [3] - The collaboration includes an upfront payment of 1.2 billion USD, with potential milestone payments totaling up to 10.2 billion USD, bringing the total deal value to a maximum of 11.4 billion USD [3] Business Development (BD) Trends - A surge in business development activities was noted, with five BD announcements totaling 4.266 billion USD made on October 16 and 17 alone [4] - Major companies involved include Hansoh Pharmaceutical, Prigen, and others, with upfront payments ranging from 0.07 billion to 1.2 billion USD [4] - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw mixed performance among its constituent stocks, with notable declines in several companies despite positive news for Innovent Biologics [4] Industry Insights - According to Huaxin Securities, the pace of outbound licensing for innovative drugs has resumed, with 93 transactions recorded by August 2025, accounting for 32% of global transactions [6] - The total upfront payments for these transactions reached 4.3 billion USD, exceeding the total for the previous year and expected to set a new high in nearly a decade [6] - The report indicates that multinational corporations (MNCs) continue to favor early-stage assets from China, particularly in hot areas like bispecific antibodies and ADCs [7] Future Outlook - The fourth quarter is expected to see concentrated BD activities, particularly with the ESMO conference and upcoming quarterly reports [7] - The trend of BD transactions is anticipated to continue as MNCs seek to fill revenue gaps from patent expirations of blockbuster products [7] - The performance of the Hong Kong Stock Connect Innovation Drug ETF (159570) has shown significant growth, with a year-to-date increase of over 109% [9]

Core Insights - The Chinese biopharmaceutical industry has achieved significant international recognition and growth, transitioning from a follower to a key contributor in the global market during the "14th Five-Year Plan" period [1][5]. Group 1: International Collaborations and Financial Milestones - In just two days, Chinese innovative drugs secured five major international deals, with several transactions exceeding $1 billion, including a $16.4 billion collaboration between Shenzhen Pruijun Biopharmaceutical Co., Ltd. and Gilead Sciences' Kite Pharma [1]. - The total value of China's innovative drug licensing agreements reached nearly $66 billion in the first half of 2025, surpassing the entire 2024 total of $51.9 billion [5]. Group 2: Technological Advancements in Drug Development - The integration of artificial intelligence and other cutting-edge technologies has transformed drug development in China, allowing for a more precise and efficient approach [2][3]. - China's share of new drug research and development has exceeded 20% globally, positioning the country as the second-largest in new drug development [2]. Group 3: Clinical Trials and International Recognition - Chinese innovative drugs are increasingly being presented at international academic conferences, demonstrating their clinical trial results that directly compete with global leading drugs [4]. - The development of new drugs such as the CDK2/4/6 inhibitor by Zhengda Tianqing Pharmaceutical Group has showcased China's capability to produce competitive therapies on the international stage [4]. Group 4: Investment in Research and Development - Chinese biopharmaceutical companies are significantly increasing their R&D investments, with some companies reporting annual R&D expenditures exceeding 4 billion yuan [4]. - The focus on original innovation and translational medicine is driving the industry towards achieving globally competitive products [5].

Core Insights - The Chinese biopharmaceutical industry is experiencing significant growth, with multiple large international deals being signed in a short period, indicating a shift from quantity to quality in innovation [1][6] - The integration of advanced technologies such as artificial intelligence and virtual cells is transforming drug development processes, allowing for more efficient and targeted research [2][3] - Chinese innovative drugs are gaining international recognition, with an increasing number of clinical trials presented at global academic conferences, showcasing their competitive efficacy against established global drugs [4][5] Group 1: International Collaborations - Shenzhen Pruijun Biopharmaceutical Co., Ltd. signed a collaboration with Gilead Sciences' Kite Pharma for in vivo editing therapy, with a potential total deal value of $1.64 billion [1] - Hansoh Pharmaceutical Group reached a licensing agreement with Roche for a targeted antibody-drug conjugate, with a potential total deal value of $1.53 billion [1] - The total value of China's innovative drug licensing agreements in the first half of 2025 is estimated to be nearly $66 billion, surpassing the total for the entire year of 2024 [6] Group 2: Technological Advancements - The Chinese biopharmaceutical industry is leveraging artificial intelligence and other cutting-edge technologies to enhance drug development, aiming to reduce traditional research timelines by 90% [2] - The establishment of digital twins and drug models for cancer patients is facilitating innovative research and accelerating new drug development [2][3] - The integration of AI, quantitative simulation, and high-throughput screening is improving research efficiency and enabling breakthroughs in drug delivery systems [3] Group 3: Clinical Recognition - The Chinese innovative drug, Moxilib Capsule, was presented at the 2025 European Society for Medical Oncology annual meeting, highlighting its clinical data [4] - Chinese drugs are increasingly participating in head-to-head trials against global leaders, demonstrating superior efficacy in various cancer treatments [4] - The focus on source innovation and disease mechanism-based research is leading to significant international achievements in the biopharmaceutical sector [5]

Major Events - Guanghe Tong (00638) has set the offer price at HKD 21.5 per share, with the public offering receiving a subscription rate of 550.99 times [1] - China Biologic Products (01177) announced the Phase III study data of Kymriah combined with Fluvestrant for the first-line treatment of advanced breast cancer will be presented at ESMO 2025 [1] - Derun Holdings (01709) plans to conduct a placement of new shares at a discount of approximately 11.34%, aiming to raise about HKD 761 million [1] - New World Development (00017) clarified media reports, stating that it has not undertaken any debt management projects regarding perpetual and other debt securities [1] - China Shenhua (01088) reported that Unit 4 of the Jiujiang Phase II project has successfully completed a 168-hour trial run [1] - Jingwei TianDi (02477) has acquired a TCSP licensed company and launched a new feature called FOPAY [1] - Rongzun International Holdings (01780) announced that its controlling shareholder intends to place up to 60% of the company's shares, reducing their stake to 15% [1] Financial Performance - Pop Mart (09992) reported a year-on-year revenue growth of 245%-250% for the third quarter [2] - China Telecom (00728) recorded a profit attributable to shareholders of RMB 30.8 billion for the first three quarters, reflecting a year-on-year increase of 5.0% [2] - Luk Fook Holdings (00590) reported that its overall retail value, retail income, and same-store sales for the second quarter exceeded the first quarter, increasing by 18%, 15%, and 10% respectively [2] - Minmetals Resources (01208) produced a total of 127,000 tons of copper in the third quarter, marking an 11% year-on-year increase [2] - Datang Power (00991) achieved a total electricity generation of approximately 2,062.41 billion kilowatt-hours in the first three quarters, up about 2.02% year-on-year [2] - Far East Horizon (03360) reported an increase in profit attributable to ordinary shareholders for the first three quarters [2] - China General Nuclear Power Corporation (01164) produced a total of 644.3 tons of natural uranium in the third quarter [2]

来源：新浪基金 10月21日，港股通创新药板块震荡回暖，100%创新药研发标的——港股通创新药ETF（520880）午后 稳定涨势，场内收涨1.21%终结两连跌。成份股荣昌生物、云顶新耀涨超4%，权重股石药集团、翰森制 药跌1%有所拖累。 【创新药"新势力"——港股通创新药ETF（520880）：纯正创新药，聚焦真龙头，港股高弹性】 港股通创新药ETF（520880）被动跟踪恒生港股通创新药精选指数，该指数完全不含CXO，100%布局 创新药研发类公司，超7成仓位押注大市值创新药龙头，是精准表征创新药硬核力量的纯正创新药指 数。场外投资者可关注其联接基金：025221。 | | | 港股通创新药ETF (520880)标的指数 前十成份股权重高达71.63%,龙头优势显著 | | | --- | --- | --- | --- | | 代码 | 简称 | 权重(%) | 总市值(亿港元) | | 6160.HK | 三济神州 | 10.47 | 3.304 | | 1177.HK | 中国生物制药 | 10.01 | 1,527 | | 1093.HK | 石药集团 | 9.58 | 1,080 | | 18 ...